Overall, 13.6% and 8.2% of FGFR2 fusions were in nonapproved breast and pancreatic cancer indications, respectively, 22.2% of FGFR3 fusions were in nonapproved NSCLC, and 19.4% and 10.2% of NRG1 fusions were in nonapproved breast and prostate cancers, respectively (Supplementary Table S11). Here, FGFR3 is linked to prostate carcinoma.